Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | JNJ-75276617 |
Trade Name | |
Synonyms | JNJ 75276617|JNJ75276617 |
Drug Descriptions |
JNJ-75276617 inhibits the interaction between menin and MLL, leading to decreased expression of target genes, potentially resulting in inhibition of cell proliferation of tumor cells harboring gene rearrangements, duplications or amplifications in KMT2A or gene alterations in NPM1 (NCI Drug Dictionary). |
DrugClasses | MEN1-KMT2A Inhibitor 6 |
CAS Registry Number | NA |
NCIT ID | C179561 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + JNJ-75276617 | Azacitidine JNJ-75276617 | 0 | 1 |
Azacitidine + JNJ-75276617 + Venetoclax | Azacitidine JNJ-75276617 Venetoclax | 0 | 1 |
Cytarabine + Dexamethasone + Fludarabine + JNJ-75276617 + Pegaspargase + Vincristine Sulfate | Cytarabine Dexamethasone Fludarabine JNJ-75276617 Pegaspargase Vincristine Sulfate | 0 | 1 |
JNJ-75276617 | JNJ-75276617 | 0 | 1 |
JNJ-75276617 + Venetoclax | JNJ-75276617 Venetoclax | 0 | 1 |